Notwithstanding that the cohort with higher CD8A and CD52 expression exhibited better event-free survival (EFS) and overall survival (OS) probabilities, independently (Fig. S2B, S2D), both of which were less expressed separately in NB patients with high-risk, MYCN amplification, progression, and advanced stage (Fig. S2C, E). This evidence concerns the gene CD52 and neuroblastoma.